1. Home
  2. CAN vs FLGT Comparison

CAN vs FLGT Comparison

Compare CAN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAN

Canaan Inc.

HOLD

Current Price

$0.42

Market Cap

486.0M

Sector

Technology

ML Signal

HOLD

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$15.94

Market Cap

511.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAN
FLGT
Founded
2013
2011
Country
Singapore
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.0M
511.2M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
CAN
FLGT
Price
$0.42
$15.94
Analyst Decision
Strong Buy
Buy
Analyst Count
6
3
Target Price
$3.21
$28.33
AVG Volume (30 Days)
9.1M
735.8K
Earning Date
05-19-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$18,730,000.00
Revenue This Year
N/A
$10.09
Revenue Next Year
$63.64
$12.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$13.46
52 Week High
$2.22
$31.04

Technical Indicators

Market Signals
Indicator
CAN
FLGT
Relative Strength Index (RSI) 40.92 39.64
Support Level $0.43 $13.46
Resistance Level $0.55 $22.48
Average True Range (ATR) 0.03 0.57
MACD -0.00 0.44
Stochastic Oscillator 25.79 65.50

Price Performance

Historical Comparison
CAN
FLGT

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

Share on Social Networks: